Salipro Biotech AB Enters into A Collaboration and License Agreement with Abcellera for Access to the Salipro® Platform for Antibody Discovery Against Gpcrs, Ion Channels, and Transporters

Salipro Biotech AB announced that it has entered into a collaboration and licensing agreement with AbCellera for access to its proprietary Salipro Platform, which stabilizes challenging G protein coupled receptor (GPCR), ion channel, and transporter antigens. Under the terms of the agreement, Salipro Biotech will receive an upfront payment, research payments and is eligible for downstream milestone payments for a defined number of targets.